Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atrasentan - Chinook Therapeutics

Drug Profile

Atrasentan - Chinook Therapeutics

Alternative Names: A 147627; A-1476271; Abbott 147627; ABT-147627; ABT-627; Atrasentan hydrochloride; CHK-01; EXV 811; EXV-811 - Novartis; Xinlay

Latest Information Update: 10 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Chinook Therapeutics
  • Class Amides; Anti-inflammatories; Antineoplastics; Benzodioxoles; Carboxylic acids; Heart failure therapies; Pyrrolidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nephrotic syndrome; IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III IgA nephropathy
  • Phase II Diabetic nephropathies; Focal segmental glomerulosclerosis; Hereditary nephritis
  • Discontinued Brain cancer; Coronary artery restenosis; Heart failure; Lung cancer; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 05 Jan 2024 SanReno Therapeutics has been acquired by Novartis
  • 30 Oct 2023 Novartis plans to submit an application for possible accelerated approval in the USA in 2024
  • 30 Oct 2023 Interim efficacy and adverse events data from a phase III ALIGN trial in IgA nephropathy released by Novartis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top